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Over the past decade, focal segmental glomerulosclerosis
(FSGS) has emerged as the most common primary
glomerulopathy in adults in the USA. However in our
practice, we became aware of increased numbers of patients
with IgA nephropathy (IgAN). In order to further examine
this, a retrospective analysis of renal biopsy diagnoses from
adults was done from our biopsy database. Adult renal
biopsies received from 3/1/2001 to 2/28/2005 were analyzed
to determine the frequency of common primary
glomerulopathies, which included FSGS, IgAN, membranous
nephropathy (MN), minimal change disease, and
membranoproliferative glomerulonephritis Type I (MPGN).
The patients were grouped as all adults (Z20 years) and
young adults (20–39 years). The distribution of common
primary glomerulopathies among the two age groups,
expressed as a percentage of all non-transplant diagnoses
(n¼ 4504), was IgAN 6.9/3.4%, FSGS 9.6/3.2%, MN 6.8/1.6%,
minimal change disease 2.5/0.9%, MPGN 1.2/0.2%. IgAN
was as common as FSGS in young adults in our biopsy
population (IgAN/FSGS 154/143 1.08:1). IgAN was the most
common primary glomerulopathy in young adult Caucasians
(IgAN/FSGS 2.1:1). IgAN was also the most common cause of
end-stage renal disease (ESRD) in young adult Caucasians. In
contrast, IgAN was rare in African Americans in whom FSGS
remains more common (FSGS/IgAN 9.7:1). These findings
from a large renal biopsy referral center serving 24
Midwestern and Southern states suggest that IgAN may be
the most common primary glomerulopathy and the most
common cause of ESRD in young adult Caucasians in the
USA.
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The most common primary glomerulopathy in the USA is
reported to be focal segmental glomerulosclerosis (FSGS).1–7
This is in contrast to reports from other parts of the world
where IgA nephropathy (IgAN) is the most common primary
glomerulopathy among all races from Europe, Asia, and
Australia with the exception of the black race.8–23 The racial
makeup of the North American population is predominantly
of European descent with a smaller mixture of other races. So
the apparently lower incidence of IgAN seen here is not easily
explained. We noticed in our renal biopsy practice that IgAN
is frequent in all age groups, but particularly common in
younger individuals. We became increasingly aware that
patients in the third and fourth decades of life, who present
with hitherto undetected chronic renal failure, often have a
diagnosis of IgAN.
Review of the literature on the incidence of various
glomerulopathies led us to suspect that FSGS cases might be
over-represented in series from metropolitan hospitals
serving large African American populations. The number of
patients with FSGS might also be inflated due to the presence
of secondary FSGS in older individuals in some studies.
Based on the above, we analyzed our renal biopsy
database, stratifying the diagnoses by age and race and
comparing the frequency of IgAN with other common
primary glomerulopathies, including FSGS, membranous
nephropathy (MN), minimal change disease, and membra-
noproliferative glomerulonephritis Type I (MPGN). If indeed
IgAN is more common as our data suggest, then new
strategies in detection and therapy may be justified since this
disease is not as benign as once considered.24
RESULTS
Out of the 4504 non-transplant renal biopsies in all adults
aged 20 years and above, 1228 cases of the major primary
glomerulopathies were identified (Table 1); and out of 1082
non-transplant renal biopsies in those aged 20–39 years, 416
cases of the major primary glomerulopathies were identified
(Table 1). Among all adults, 435 had FSGS and 313 had
IgAN. (IgAN:FSGS H 0.72:1). However, in the young adults
(aged 20–39 years), there were 154 instances of IgAN and 143
of FSGS (IgAN:FSGS H 1.08:1). The male to female ratio of
IgAN among all adults was 200:113 (1.8:1) and 94:60 (1.6:1)
in those aged 20–39 years. The distribution of cases of IgAN
and FSGS in adults every half decade from age 20 years
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onwards is shown in Figure 1. The peak incidence of IgAN
was in the third and fourth decades of life with a gradual
decline over the remaining years. The peak incidence of FSGS
is in the fourth decade, with a secondary peak in the seventh
decade of life. IgAN was the most common primary
glomerulopathy in the third decade of life (IgAN/FSGS 77/
49 1.57:1). In the fourth decade of life, the ratio of IgAN/
FSGS was 78/95 (0.82/1.0). IgAN was also slightly more
common than FSGS in all young adults aged 20–39 years 154/
143 (1.08/1).
Race information was available for 216 patients (72.7%) in
the young adult group with either FSGS or IgAN (Tables 2
and 3). In all, 118 patients were Caucasian, 64 African
American, 17 Hispanic, 13 Asian, two East Indian, one Native
American, and one Filipino/Caucasian (Table 2). IgAN was
the most common primary glomerulopathy in Caucasians
aged 20–39 years (IgAN/FSGS 80/38 2.1:1) as opposed to
African Americans in whom FSGS was more common (FSGS/
IgAN 58/6 9.7:1) (Table 2).
Follow-up time in this study is very brief and follow-up
history was available in 149 (50.1%) of young adult patients
with IgAN/FSGS. Yet, 26 patients from this group have
progressed to end-stage renal disease (ESRD) (Table 3). Of
the 13 African Americans with ESRD, FSGS was the primary
diagnosis in 12 and IgAN in one. However, of the 10
Caucasians with ESRD, IgAN was the primary diagnosis in
eight and FSGS in two.
DISCUSSION
In the USA, epidemiological studies of the general population
pertaining to both IgAN and FSGS are lacking. Reports that
show increased incidence of FSGS are mostly from metro-
politan hospitals which serve a large African American
population.1,2,4–6 Some of these studies do not provide
information on IgAN and some deal primarily with diseases
causing nephrotic syndrome rather than primary glomerulo-
pathy and exclude IgAN. The largest epidemiological study
available is from the United States Renal Data System
(USRDS) databank.25 However, this databank only includes
ESRD patients. While USRDS data may give a broad idea of
incidence and prevalence of the two diseases, an accurate
assessment of incidence and prevalence may not be possible
as the progression to ESRD differs between patients with
FSGS and IgAN.
Awareness that IgAN is more common in the USA than
previously reported is slowly emerging. Only one epidemio-
logical survey of a localized area in the USA is available for
IgAN but not for FSGS and other primary glomerulopathies.
This study of Central and Eastern Kentucky indeed shows
that the incidence of ESRD due to IgAN nephropathy has
increased from 5.4 to 12.4 patients per million population
over a period of 20 years from 1975–1994.26 According to
USRDS (The data reported here has been supplied by the
USRDS. The interpretation and reporting of these data are
the responsibility of the author(s) and in no way should be
seen as an official policy or interpretation of the US
government) data, the incidence of ESRD due to IgAN has
increased 45-fold from 0.16 to 3% over a period of 20 years.3
A small biopsy series from a military hospital shows that
IgAN is far more common in young white individuals than
FSGS (40 IgAN H 8 FSGS), while the reverse was true in
black indivisuals (0 IgAN H 66 FSGS).6 Another small biopsy
Table 1 | Distribution of common primary glomerulopathies
Age IgAN FSGS MN Minimal change disease MPGN Total
Z20a 313 (6.9%) 435 (9.6%) 310 (6.8%) 116 (2.5%) 54 (1.2%) 1228
20–39b 154 (14.2%) 143 (13.2%) 70 (6.5%) 42 (3.9%) 7 (0.6%) 416
aExpressed as a percentage of all adult biopsies (n=4504).
bExpressed as a percentage of biopsies in young adults (n=1082).
FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis Type I.
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Figure 1 | Distribution of IgAN and FSGS in adults from the
Nephropathology Associates database.
Table 2 | Distribution of IgAN/FSGS among races in young
adults
AA Cau Hisp Asian Other Total
IgAN 6 80 9 10 2 107
FSGS 58 38 8 3 2 109
Total 64 118 17 13 4 216
AA, African American; Cau, Caucasian; Hisp, Hispanic; FSGS, focal segmental
glomerulosclerosis; IgAN, IgA nephropathy.
Table 3 | ESRD in various races among young adults
AA Cau Hisp Other Total
IgAN 1 8 0 1 10
FSGS 12 2 1 1 16
Total 13 10 1 2 26
AA, African American; Cau, Caucasian; Hisp, Hispanic; ESRD, end-stage renal disease;
FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy.
Renal function follow-up data was available on 149 young adults with IgAN/FSGS.
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series from a community hospital has shown IgAN to be the
cause of 51% of primary glomerulopathies in young
Caucasian adults.5 The current study is the largest and only
biopsy series which specifically addresses the frequency of
IgAN in biopsies of adults across various age groups in the
USA. Our data show that IgAN is as common as FSGS in
young adults when all races were considered. In African
Americans, FSGS remains the most common primary
glomerulopathy. However in Caucasians, who constitute
67.4% of the US population,27 IgAN is the most common
primary glomerulopathy.
In countries where systematic screening for urinary
abnormalities is done, IgAN is by far the most frequent
primary glomerulopathy.28 Since the early studies were
primarily out of Asia, the high frequency of IgAN was at
first thought to be limited to those of Asian origin. However,
reports documenting that IgAN is the most common primary
glomerulopathy in Finland, France, Italy, the UK, Germany,
Australia, etc. suggest otherwise.9,10,14–16,20,28
Thus, it would seem that IgAN is not actually less
common in the USA, but less commonly diagnosed. The
criteria for biopsying patients with hematuria varies among
nephrologists and most do not do a renal biopsy unless, in
addition to hematuria, there is nephrotic range proteinuria
and/or evidence of renal dysfunction.28,29 This would result
in detection of the disease only in those already at a more
advanced stage, underestimating the total population of
patients with IgAN and selecting for those with potentially a
much poorer outcome.11,28 In addition, the number of IgAN
cases may be underestimated because some renal pathologists
in the USA use the criteria of more than 1þ staining
intensity to render a definitive diagnosis of IgAN.30 However,
it is very possible that ‘early’, ‘quiescent’, or ‘burned-out’
IgAN would have trace to 1þ amounts of IgA staining which
would then be ignored or reported as a non-specific finding.
Given the variable light microscopy changes seen in IgAN,
some of these cases could actually end up being called FSGS
further tilting the data.
Imprecision of diagnostic criteria for FSGS may also
falsely inflate the number of patients in that category leading
to an inappropriately higher incidence of FSGS in compar-
ison to the more strictly defined IgAN. For example, in the
USRDS databank, the category focal glomerulosclerosis/focal
glomerulonephritis includes not only typical FSGS but also
other entities such as focal global glomerulosclerosis or focal
glomerulonephritis of an inflammatory type. Finally, the
difficulty in distinguishing between primary and secondary
FSGS is well known.31
Recent reports document that IgAN is the most common
primary glomerulopathy in Hispanics and that the frequency
of ESRD due to IgAN has dramatically increased in this
ethnic group.3,7 Specific data from Hispanic patients in our
study is too limited to draw conclusions. However, the
Hispanic population is projected to double to 24.4% nation-
wide by 2050 emphasizing the importance of monitoring this
group for primary glomerular disease, particular IgAN.
An increase in the incidence of IgAN can be expected over
the coming decades due to changes in awareness and biopsy
practices, and evolving population demographics. This
suggests the need for a comprehensive epidemiological
investigation into the prevalence and incidence of IgAN in
the US population. Is ESRD due to IgAN more common than
recognized, especially in young adults? If so, is a screening
program for IgAN justifiable in the USA as in some other
countries such as Japan and Singapore where systematic
screening reveals an incidence of IgAN as high as 50% of all
primary glomerulopathies?28 Also, in some studies, younger
age at presentation is associated with a more rapid progression
to ESRD.29,32 All this has special significance as disease-
modifying agents are available for IgAN especially if detected
early in the course of the disease.33,34 The current study
provides data to support the impression that IgAN is under-
recognized in the USA. This is the largest biopsy series
comparing the incidence of IgAN and FSGS in young adults. It
is also the first study to show that IgAN is as common as FSGS
in young adults, and that IgAN is the most common primary
glomerulopathy in young adult Caucasians. In addition, this
study suggests that IgAN may be the most common primary
glomerulopathy causing ESRD in young adult Caucasians.
MATERIALS AND METHODS
All kidney biopsies received at Nephropathology Associates over a
4-year period from March 1, 2001 to February 28, 2005 were
reviewed. The biopsies were from 24 states of the USA predominantly
from the South and the Mid-West regions. Patients were classified by
age into two categories: all adults – those 20 years and older and
young adults – those 20–39 years of age. The age group 20–39 years
was chosen for specific emphasis for the following reasons:
(1) o40 years to reduce the effect of unrelated chronic hyperten-
sion and other diseases resulting in secondary FSGS;
(2) 419 years to eliminate pediatric FSGS which is considered by
many to be different from adult FSGS and because children
with isolated microscopic hematuria are typically not biopsied
in the USA, likely leading to underestimation of IgAN in this
age group.
All cases of IgAN with a secondary cause such as liver disease,
autoimmune disorders, and systemic conditions such as Henoch–
Schonlein nephritis and other vasculitides were eliminated. All cases
of FSGS in which a secondary cause was identified were eliminated.
These included diabetes mellitus, HIV, chronic hypertension,
immune complex-mediated glomerulonephritis, solitary kidney,
obesity, and others. Secondary forms of other primary glomerulo-
pathies were also excluded from analysis. All cases of MN secondary
to autoimmune disorders such as systemic lupus erythematosus and
rheumatoid arthritis were eliminated. Minimal change disease due
to secondary causes such as malignancy and those with associated
positive anti-nuclear antibody were excluded. MPGN cases asso-
ciated with lupus nephritis were excluded. Finally, in the rare
instances where repeat biopsies were present, only the first biopsy
was included in the study. For the histopathological diagnosis of
IgAN, a staining intensity of 2–3þ (out of a maximum of three) in
mesangial areas was used. Biopsies with staining intensity of 1 or less
were not classified as IgAN.
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Clinical data were gathered from the biopsy request forms. In
addition, a questionnaire was sent to the referring physicians asking
for race information and renal function data on all patients aged
20–39 years with a diagnosis of either FSGS or IgAN. Data for IgAN
were compared against that for FSGS (the most commonly reported
primary glomerulopathy) to assess incidence of disease, ESRD, and
race in young adults.
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